Summary

The global nucleic acid therapeutics, sport food additives and skin care market is expected to reach USD 22.00 billion by 2032 from USD 12.78 billion in 2024, growing with a substantial CAGR of 7.06% in the forecast period of 2025 to 2032.

Market Segmentation:
Global Nucleic Acid Therapeutics, Sport Food Additives and Skin Care Market, By Product (Nucleic Acid Therapeutic, Nucleic Acid Skin Care Products, and Nucleic Acid Sports Food Additives), Source (Natural Nucleic Acids and Synthetic Nucleic Acids), End User (Individual Consumers/ Home Healthcare, and Professional/Facility Use), Distribution Channel (Direct Tender, Retail Sales, and Others), Countries (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Belgium, Netherlands, Denmark, Switzerland, Norway, Sweden, Finland, Turkey, Poland, Rest of Europe, China, Japan, South Korea, India, Taiwan, Australia, Indonesia, Singapore, New Zealand, Thailand, Malaysia, Viet Nam, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, U.A.E., Saudi Arabia, Qatar, South Africa, Kuwait, Egypt, Bahrain, Oman, and Rest of Middle East & Africa) - Industry Trends and Forecast to 2032


Overview for Global Nucleic Acid Therapeutics, Sport Food Additives and Skin Care Market Dynamics:

Driver
• Growing demand for functional foods, nutraceuticals, and bioactive skincare ingredients
Restraint
• High costs associated with production and research & development
Opportunity
• Breakthroughs in RNA and DNA-based therapies, food additives, and skincare innovations
Market Players:

The key players operating in the global nucleic acid therapeutics, sport food additives and skin care market are:
• Pfizer Inc.
• Novartis AG
• AstraZeneca
• Sarepta Therapeutics, Inc.
• Alnylam Pharmaceuticals, Inc.
• Zhejiang Haichang Biopharmaceutical Technology Co., Ltd.
• Moderna, Inc.
• Biogen
• Ionis Pharmaceuticals, Inc.
• Spark Therapeutics, Inc.
• SKINSHIFT
• DNA Skin Institute
• Remy Laure
• Juliette Armand
• The Naked Chemist
• PostQuam
• Shopatdna
• Kalichem s.r.l.
• MoonGlow
• Bio Jouvance Paris Consumer
• NEOVA

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 224
1.1 OBJECTIVES OF THE STUDY 224
1.2 MARKET DEFINITION 224
1.3 OVERVIEW 224
1.4 LIMITATIONS 227
1.5 MARKETS COVERED 227
2 MARKET SEGMENTATION 239
2.1 MARKETS COVERED 239
2.2 GEOGRAPHICAL SCOPE 240
2.3 YEARS CONSIDERED FOR THE STUDY 241
2.4 CURRENCY AND PRICING 241
2.5 DBMR TRIPOD DATA VALIDATION MODEL 242
2.6 MULTIVARIATE MODELING 245
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 246
2.8 DBMR MARKET POSITION GRID 247
2.9 DBMR VENDOR SHARE ANALYSIS 249
2.10 MARKET END USER COVERAGE GRID 251
2.11 SECONDARY SOURCES 253
2.12 ASSUMPTIONS 253
3 EXECUTIVE SUMMARY 254
4 PREMIUM INSIGHTS 259
4.1 PESTAL ANALYSIS 263
4.2 PORTER’S FIVE FORCES 264
4.2.1 THREAT OF NEW ENTRANTS 264
4.2.2 BARGAINING POWER OF BUYERS 265
4.2.3 BARGAINING POWER OF SUPPLIERS 265
4.2.4 THREAT OF SUBSTITUTES 265
4.2.5 COMPETITIVE RIVALRY 266
4.3 IMPORT EXPORT SCENARIO 267
4.4 PRICING ANALYSIS 268
4.5 PRODUCTION CAPACITY FOR TOP MANUFACTURERS 269
4.6 BRAND OUTLOOK 270
4.6.1 BRAND COMPARATIVE ANALYSIS OF GLOBAL NUCLEIC ACID SPORT FOOD ADDITIVES AND SKIN CARE MARKET 270
4.6.2 PRODUCT VS BRAND OVERVIEW 271
4.6.2.1 PRODUCT OVERVIEW 271
4.6.2.2 BRAND OVERVIEW 272
4.7 CONSUMER BUYING BEHAVIOUR FOR THE GLOBAL NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND GLOBAL NUCLEIC ACID SKIN CARE MARKET 273
4.7.1 AWARENESS AND EDUCATION 273
4.7.2 HEALTH AND PERFORMANCE-ORIENTED BUYERS 273
4.7.3 PREFERENCE FOR NATURAL AND SCIENTIFIC FORMULATIONS 273
4.7.4 PRICE SENSITIVITY AND WILLINGNESS TO PAY FOR QUALITY 274
4.7.5 ROLE OF BRAND TRUST AND REVIEWS 274
4.7.6 DIGITAL-FIRST SHOPPING EXPERIENCE 274
4.7.7 REGULATORY AND SAFETY CONCERNS 275
4.7.8 SUSTAINABILITY AND ETHICAL CONSIDERATIONS 275
4.8 FACTORS AFFECTING BUYING DECISION FOR GLOBAL NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND GLOBAL NUCLEIC ACID SKIN CARE MARKET 276
4.8.1 SCIENTIFIC VALIDATION AND EFFICACY 276
4.8.2 PRICE AND PERCEIVED VALUE 276
4.8.3 BRAND REPUTATION AND TRUST 276
4.8.4 PERSONAL HEALTH AND SKIN CONCERNS 277
4.8.5 DIGITAL INFLUENCE AND E-COMMERCE ACCESSIBILITY 277
4.8.6 REGULATORY APPROVALS AND SAFETY ASSURANCE 277
4.8.7 ETHICAL AND SUSTAINABILITY CONSIDERATIONS 278
4.8.8 AVAILABILITY AND CONVENIENCE 278
4.9 IMPACT OF ECONOMIC SLOWDOWN ON GLOBAL NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND GLOBAL NUCLEIC ACID SKIN CARE MARKET 279
4.9.1 IMPACT ON PRICE 279
4.9.2 IMPACT ON SUPPLY CHAIN 279
4.9.3 IMPACT ON SHIPMENT 279
4.9.4 IMPACT ON DEMAND 279
4.9.5 IMPACT ON STRATEGIC DECISIONS 280
4.10 PRODUCT ADOPTION SCENARIO FOR GLOBAL NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND GLOBAL NUCLEIC ACID SKIN CARE MARKET 281
4.10.1 AWARENESS AND MARKET PENETRATION 281
4.10.2 CONSUMER SEGMENTATION AND ADOPTION TRENDS 281
4.10.3 INFLUENCE OF SCIENTIFIC RESEARCH AND REGULATORY APPROVALS 282
4.10.4 PRICING, ACCESSIBILITY, AND DISTRIBUTION CHANNELS 282
4.11 RAW MATERIAL SOURCING ANALYSIS 284
4.11.1 SOURCES OF NUCLEIC ACIDS FOR FOOD ADDITIVES AND SKINCARE 284
4.11.2 SUPPLY CHAIN CHALLENGES IN RAW MATERIAL PROCUREMENT 284
4.11.3 QUALITY CONTROL AND REGULATORY COMPLIANCE 284
4.11.4 COST IMPLICATIONS OF RAW MATERIAL SOURCING 284
4.11.5 SUSTAINABILITY AND ETHICAL SOURCING 284
4.12 SUPPLY CHAIN ANALYSIS FOR GLOBAL NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND GLOBAL NUCLEIC ACID SKIN CARE MARKETS 286
4.13 OVERVIEW 286
4.13.1 LOGISTIC COST SCENARIO 286
4.13.2 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 286
4.14 PATENT ANALYSIS 287
4.15 PIPELINE 290
4.16 MERGERS & ACQUISITIONS 293
4.17 INDUSTRY INSIGHTS 294
5 PIPELINE ANALYSIS: 302
6 EPIDEMIOLOGY 308
6.1 INCIDENCE BY GENDER 308
6.2 TREATMENT RATES 308
6.3 MORTALITY RATES 308
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODELS 309
6.5 PATIENT TREATMENT SUCCESS RATES 309
7 REGULATORY COVERAGE 311
8 MARKET OVERVIEW 312
8.1 DRIVERS 314
8.1.1 GROWING DEMAND FOR FUNCTIONAL FOODS, NUTRACEUTICALS, AND BIOACTIVE SKINCARE INGREDIENTS 314
8.1.2 RISING INFLUENCE OF PERSONALIZED MEDICINE AND CUSTOMIZED SKINCARE SOLUTIONS 315
8.1.3 FAVORABLE REGULATORY POLICIES AND RISING R&D INVESTMENTS IN GENE-BASED THERAPIES 316
8.1.4 INCREASING PREVALENCE OF CHRONIC DISEASES AND AN AGING GLOBAL POPULATION 317
8.2 RESTRAINTS 319
8.2.1 INCREASING TREATMENT COSTS DUE TO HIGH PRODUCTION EXPENSES IN GENE-BASED THERAPIES 319
8.2.2 POTENTIAL RISKS AND SIDE EFFECTS OF GENE-BASED TREATMENTS 320
8.3 OPPORTUNITIES 321
8.3.1 BREAKTHROUGHS IN RNA AND DNA-BASED THERAPIES, FOOD ADDITIVES, AND SKINCARE INNOVATIONS 321
8.3.2 EXPANSION THROUGH STRATEGIC PARTNERSHIPS AND COLLABORATIONS 322
8.3.3 TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY SYSTEMS 323
8.4 CHALLENGES 325
8.4.1 LOW PUBLIC AWARENESS AND SLOW ADOPTION RATES 325
8.4.2 INTELLECTUAL PROPERTY COMPLEXITIES AND PATENT-RELATED HURDLES 326
9 GLOBAL NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY PRODUCT 327
9.1 OVERVIEW 328
9.2 NUCLEIC ACID THERAPEUTICS 329
9.2.1 BY CATEGORY 330
9.2.1.1 ANTISENSE 330
9.2.1.1.1 BY MOLECULES 330
9.2.1.1.1.1 NUSINERSEN 331
9.2.1.1.1.2 ETEPLIRSEN 331
9.2.1.1.1.3 GOLODIRSEN 331
9.2.1.1.1.4 INOTERSEN 331
9.2.1.1.1.5 VOLANESORSEN 331
9.2.1.1.1.6 OTHERS 331
9.2.1.1.2 BY DRUGS 331
9.2.1.1.2.1 SPINRAZA 331
9.2.1.1.2.2 EXONDYS 51 331
9.2.1.1.2.3 TEGSEDI 331
9.2.1.1.2.4 OTHERS 331
9.2.2 RNA INTERFERENCE 332
9.2.2.1 BY MOLECULES 332
9.2.2.1.1 VUTRISIRAN 332
9.2.2.1.2 GIVOSIRAN 332
9.2.2.1.3 PATISIRAN 332
9.2.2.1.4 LUMASIRAN 332
9.2.2.2 BY DRUGS 333
9.2.2.2.1 AMVUTRA 333
9.2.2.2.2 GIVLAARI 333
9.2.2.2.3 ONPATTRO 333
9.2.2.2.4 OXLUMO 333
9.2.2.3 BY TYPE 334
9.2.2.3.1 DOUBLE-STRANDED RNA VIRUSES (DSRNA) 334
9.2.2.3.2 SMALL INTERFERING RNA (SIRNA) 334
9.2.2.3.3 MICRORNAS (MIRNA) 334
9.2.3 CPG OLIGONUCLEOTIDES 335
9.2.3.1 BY TYPE 335
9.2.3.1.1 CPG ADJUVANTS IN VACCINES 335
9.2.3.1.2 TYPE B CPG OLIGONUCLEOTIDES 335
9.2.4 APTAMERS 335
9.2.5 OTHERS 335
9.2.6 BY STRUCTURE 336
9.2.6.1 SINGLE-STRANDED RNA 336
9.2.6.2 DOUBLE-STRANDED DNA 336
9.2.6.3 SINGLE-STRANDED DNA 336
9.2.6.4 SINGLE-STRANDED RNA/DNA 336
9.2.7 BY DRUG TYPE 337
9.2.7.1 MARKETED/ APPROVED DRUGS 337
9.2.7.1.1 SMALL NUCLEIC ACID DRUGS 337
9.2.7.1.2 MRNA VACCINES 337
9.2.7.1.3 OTHERS 337
9.2.7.2 PIPELINE DRUGS 337
9.2.8 BY APPLICATION 338
9.2.8.1 GENETIC DISORDERS 338
9.2.8.2 NEUROLOGICAL DISORDERS 338
9.2.8.3 INFECTIOUS DISEASES 338
9.2.8.4 AUTOIMMUNE DISEASES 338
9.2.8.5 OTHERS 338
9.2.9 BY ROUTE OF ADMINISTRATION 339
9.2.9.1 INTRATHECAL 339
9.2.9.2 SUBCUTANEOUS 339
9.2.9.3 INTRAVENOUS 339
9.2.9.4 OTHERS 339
9.3 NUCLEIC ACID SKIN CARE PRODUCTS 340
9.3.1 DNA-BASED SKIN CARE 341
9.3.1.1 DNA REPAIR SERUMS 341
9.3.1.1.1 ANTI-AGING DNA SERUMS 341
9.3.1.1.2 HYDRATING DNA SERUMS 341
9.3.1.1.3 DNA-BASED COLLAGEN-BOOSTING SERUMS 341
9.3.2 DNA-INFUSED MOISTURIZERS 342
9.3.2.1.1 DAY CREAMS 342
9.3.2.1.2 NIGHT CREAMS 342
9.3.2.1.3 DEEP HYDRATION CREAMS 342
9.3.2.1.4 OTHERS 342
9.3.2.2 DNA-BASED SUNSCREENS 342
9.3.2.2.1 BROAD-SPECTRUM UV PROTECTION 342
9.3.2.2.2 ANTI-PHOTOAGING DNA SUNSCREENS 342
9.3.2.3 DNA-BASED FACE MASKS 343
9.3.2.3.1 SHEET MASKS 343
9.3.2.3.2 CLAY MASKS 343
9.3.2.3.3 GEL MASKS 343
9.3.2.3.4 OTHERS 343
9.3.2.4 DNA-INFUSED EYE CREAMS 344
9.3.2.4.1 ANTI-DARK CIRCLE CREAMS 344
9.3.2.4.2 FINE LINE & WRINKLE REDUCTION CREAMS 344
9.3.2.4.3 PUFFINESS REDUCTION CREAMS 344
9.3.2.4.4 OTHERS 344
9.4 RNA-BASED SKIN CARE 345
9.4.1 RNA-INFUSED CREAMS 345
9.4.1.1 ANTI-AGING RNA CREAMS 345
9.4.1.2 BARRIER REPAIR CREAMS 345
9.4.1.3 INTENSIVE MOISTURE CREAMS 345
9.4.1.4 OTHERS 345
9.4.2 RNA-BASED ANTI-AGING TREATMENTS 346
9.4.2.1 WRINKLE REDUCTION FORMULATIONS 346
9.4.2.2 SKIN REJUVENATION TREATMENTS 346
9.4.2.3 OTHERS 346
9.4.3 GENE THERAPY-INFUSED SKIN CARE PRODUCTS 347
9.4.3.1 PERSONALIZED SKINCARE WITH DNA/RNA MODIFICATIONS 347
9.4.3.2 EPIGENETIC SKIN CARE TREATMENTS 347
9.4.3.3 OTHERS 347
9.4.4 BY SKIN TYPE 348
9.4.4.1 DRY SKIN 348
9.4.4.2 NORMAL SKIN 348
9.4.4.3 OILY SKIN 348
9.4.4.4 COMBINATION SKIN 348
9.4.4.5 SENSITIVE SKIN 348
9.4.4.6 OTHERS 348
9.4.5 BY PACKAGING 349
9.4.5.1 BOTTLES 349
9.4.5.1.1 SQUEEZE BOTTLES 349
9.4.5.1.2 PUMP BOTTLES 349
9.4.5.1.3 SPRAY BOTTLES 349
9.4.5.1.4 OTHERS 349
9.4.5.2 TUBES 350
9.4.5.2.1 TWIST CAPS 350
9.4.5.2.2 FLIP-TOP CAPS 350
9.4.5.2.3 AIRLESS SQUEEZE TUBES 350
9.4.5.2.4 OTHERS 350
9.4.5.3 DROPPER BOTTLES 351
9.4.5.3.1 PIPETTE DROPPERS 351
9.4.5.3.2 PUSH-BUTTON DROPPERS 351
9.4.5.4 JARS 351
9.4.5.4.1 SCREW-TOP LIDS 351
9.4.5.4.2 FLIP-TOP LIDS 351
9.4.5.4.3 SPATULA-INCLUDED JARS 351
9.4.5.4.4 OTHERS 351
9.4.5.5 AMPOULES 352
9.4.5.5.1 SINGLE-USE AMPOULES 352
9.4.5.5.2 MULTI-DOSE AMPOULES 352
9.4.5.6 SACHETS AND POUCHES 353
9.4.5.6.1 TEAR-OFF SACHETS 353
9.4.5.6.2 RESEALABLE POUCHES 353
9.4.5.7 OTHERS 353
9.4.6 BY PACKAGING SIZE 354
9.4.6.1 MEDIUM-SIZED PACKAGING (31 ML – 75 ML) 354
9.4.6.2 SMALL-SIZED PACKAGING (1 ML – 30 ML) 354
9.4.6.3 LARGE-SIZED PACKAGING (76 ML – 200 ML) 354
9.4.6.4 EXTRA-LARGE PACKAGING (ABOVE 200 ML) 354
9.4.7 BY PRICE RANGE 355
9.4.7.1 MASS 355
9.4.7.2 PREMIUM 355
9.4.7.3 LUXURY 355
9.4.8 BY APPLICATION 356
9.4.8.1 MOISTURIZATION & HYDRATION 356
9.4.8.1.1 DEEP HYDRATION WITH NUCLEIC ACIDS 357
9.4.8.1.1.1 DNA-BASED WATER-LOCK CREAMS 357
9.4.8.1.1.2 RNA-POWERED HYDRATION BOOSTERS 357
9.4.8.1.2 LONG-LASTING HYDRATION SERUMS 357
9.4.8.1.2.1 24-HOUR HYDRATION RNA SERUMS 357
9.4.8.1.2.2 DNA-POWERED MOISTURE-LOCKING TREATMENTS 357
9.4.8.1.3 SKIN BARRIER STRENGTHENING 358
9.4.8.1.3.1 NUCLEIC ACID-INFUSED CERAMIDE CREAMS 358
9.4.8.1.3.2 EPIGENETIC SKIN RESILIENCE ENHANCERS 358
9.4.8.2 SKIN REGENERATION & REPAIR 359
9.4.8.2.1 POST-SURGERY & INTENSIVE HEALING TREATMENTS 359
9.4.8.2.2 DNA-BASED WOUND HEALING CREAMS 359
9.4.8.2.3 RNA-INFUSED SCAR-REPAIR SERUMS 359
9.4.8.2.4 SKIN BARRIER RECOVERY FORMULATIONS 359
9.4.8.2.5 CELLULAR RENEWAL TREATMENTS 360
9.4.8.2.5.1 DNA-STIMULATING SKIN RENEWAL SERUMS 360
9.4.8.2.5.2 RNA-BASED ENZYMATIC SKIN REPAIR MASKS 360
9.4.8.2.6 DNA DAMAGE REPAIR 360
9.4.8.2.6.1 UV-INDUCED DNA DAMAGE REVERSAL CREAMS 360
9.4.8.2.6.2 EPIGENETIC REPAIR SERUMS 360
9.4.8.2.6.3 OTHERS 360
9.4.8.3 UV PROTECTION & SUN DAMAGE REPAIR 361
9.4.8.3.1 DNA-BASED SUNSCREENS 361
9.4.8.3.1.1 BROAD-SPECTRUM UVA/UVB PROTECTION 361
9.4.8.3.1.2 PHOTOAGING DEFENSE FORMULAS 361
9.4.8.3.2 AFTER-SUN DNA REPAIR TREATMENTS 362
9.4.8.3.2.1 DNA-INFUSED POST-SUN EXPOSURE MASKS 362
9.4.8.3.2.2 RNA-BASED SUNBURN RECOVERY GELS 362
9.4.8.3.3 BLUE LIGHT & POLLUTION PROTECTION 362
9.4.8.3.3.1 DNA-POWERED DIGITAL DEFENSE CREAMS 362
9.4.8.3.3.2 RNA-BASED ENVIRONMENTAL SHIELD SERUMS 362
9.4.8.4 ACNE & SCAR TREATMENT 363
9.4.8.4.1 DNA-BASED ACNE CONTROL SERUMS 363
9.4.8.4.1.1 ANTI-BACTERIAL NUCLEIC ACID SERUMS 363
9.4.8.4.1.2 SEBUM-REGULATING RNA TREATMENTS 363
9.4.8.4.2 RNA-POWERED SCAR FADING CREAMS 364
9.4.8.4.2.1 POST-ACNE MARK CORRECTORS 364
9.4.8.4.2.2 EPIGENETIC TISSUE REGENERATION SERUMS 364
9.4.8.4.3 HORMONAL ACNE TREATMENTS 364
9.4.8.4.3.1 DNA-BASED HORMONAL BALANCING SKINCARE 364
9.4.8.4.3.2 RNA-INFUSED ANTI-INFLAMMATORY GELS 364
9.4.8.4.4 OIL-CONTROL & PORE REDUCTION 365
9.4.8.4.4.1 DNA-POWERED OIL-BALANCING CREAMS 365
9.4.8.4.4.2 RNA-BASED PORE-TIGHTENING TONERS 365
9.4.8.5 HYPERPIGMENTATION & DARK SPOT TREATMENT 366
9.4.8.5.1 DARK SPOT CORRECTORS 366
9.4.8.5.1.1 DNA-BASED SPOT FADING TREATMENTS 366
9.4.8.5.1.2 RNA-POWERED DISCOLORATION REDUCERS 366
9.4.8.5.2 UNEVEN SKIN TONE CORRECTION 367
9.4.8.5.2.1 DNA-BASED SKIN BRIGHTENING MASKS 367
9.4.8.5.2.2 GENE-TARGETED EVEN SKIN TONE SOLUTIONS 367
9.4.8.5.3 MELANIN-INHIBITING SERUMS 367
9.4.8.5.3.1 DNA-BASED TYROSINASE INHIBITORS 367
9.4.8.5.3.2 RNA-POWERED BRIGHTENING SERUMS 367
9.4.8.5.4 POST-INFLAMMATORY HYPERPIGMENTATION (PIH) TREATMENTS 368
9.4.8.5.4.1 NUCLEIC ACID-INFUSED ACNE MARK CORRECTORS 368
9.4.8.5.4.2 RNA-BASED REDNESS-REDUCING CREAMS 368
9.4.8.6 ANTI-AGING & WRINKLE REDUCTION 369
9.4.8.6.1 COLLAGEN-BOOSTING FORMULATIONS 369
9.4.8.6.1.1 DNA-INFUSED COLLAGEN SERUMS 369
9.4.8.6.1.2 RNA-BASED PEPTIDE BOOSTERS 369
9.4.8.6.1.3 GENE-STIMULATING COLLAGEN MASKS 369
9.4.8.6.1.4 OTHERS 369
9.4.8.6.2 SKIN FIRMING & ELASTICITY IMPROVEMENT 370
9.4.8.6.2.1 DNA-BASED SKIN TIGHTENING SERUMS 370
9.4.8.6.2.2 RNA-POWERED ELASTICITY-ENHANCING CREAMS 370
9.4.8.6.2.3 NUCLEIC ACID-INFUSED FACIAL LIFTING MASKS 370
9.4.8.6.2.4 OTHERS 370
9.4.8.6.3 FINE LINE TREATMENT 371
9.4.8.6.3.1 FOREHEAD LINE CORRECTORS 371
9.4.8.6.3.2 CROW’S FEET REDUCTION CREAMS 371
9.4.8.6.3.3 UNDER-EYE WRINKLE SERUMS 371
9.4.8.6.3.4 NASOLABIAL FOLD TREATMENT 371
9.4.8.6.3.5 OTHERS 371
9.4.8.6.4 DEEP WRINKLE REPAIR 372
9.4.8.6.4.1 DNA-BASED RETINOL ALTERNATIVES 372
9.4.8.6.4.2 EPIGENETIC WRINKLE-REDUCING SERUMS 372
9.4.8.6.4.3 OTHERS 372
9.4.8.7 SENSITIVE SKIN CARE & INFLAMMATION REDUCTION 373
9.4.8.7.1 SOOTHING & ANTI-REDNESS FORMULATIONS 373
9.4.8.7.1.1 RNA-BASED ROSACEA TREATMENTS 373
9.4.8.7.1.2 DNA-INFUSED CALMING MASKS 373
9.4.8.7.2 HYPOALLERGENIC DNA-BASED SKINCARE 374
9.4.8.7.2.1 SENSITIVE SKIN RNA CREAMS 374
9.4.8.7.2.2 FRAGRANCE-FREE DNA SERUMS 374
9.4.8.7.3 ANTI-INFLAMMATORY NUCLEIC ACID TREATMENTS 374
9.4.8.7.3.1 DNA-POWERED CYTOKINE-REDUCING SERUMS 374
9.4.8.7.3.2 RNA-BASED IRRITATION-REDUCING GELS 374
9.5 NUCLEIC ACID SPORTS FOOD ADDITIVES 375
9.5.1 SPORTS SUPPLEMENTS 376
9.5.1.1 POWDER 376
9.5.1.2 CAPSULES 376
9.5.1.3 OTHERS 376
9.5.2 SPORTS FOOD 376
10 GLOBAL NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY SOURCE 377
10.1 OVERVIEW 378
10.2 NATURAL NUCLEIC ACIDS 379
10.2.1 PLANT-BASED 380
10.2.2 MARINE-DERIVED 380
10.2.3 OTHERS 380
10.3 SYNTHETIC NUCLEIC ACIDS 380
11 GLOBAL NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY END USER 381
11.1 OVERVIEW 382
11.2 INDIVIDUAL CONSUMERS/ HOME HEALTHCARE 383
11.2.1 WOMEN 384
11.2.2 MEN 384
11.2.3 UNISEX 384
11.3 PROFESSIONAL/FACILITY USE 384
11.3.1 DERMATOLOGY CLINICS 385
11.3.2 BEAUTY SALONS & SPAS 385
11.3.3 SPECIALTY CLINICS 385
11.3.4 HOSPITAL 385
11.3.5 OTHERS 385
12 GLOBAL NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY DISTRIBUTION CHANNEL 386
12.1 OVERVIEW 387
12.2 DIRECT TENDER 388
12.3 RETAIL SALES 389
12.3.1 BY TYPE 389
12.3.1.1 STORE BASED 390
12.3.1.1.1 SUPERMARKETS/HYPERMARKETS 390
12.3.1.1.2 SPECIALTY BEAUTY STORES 390
12.3.1.1.3 PHARMACIES & DRUGSTORES 390
12.3.1.1.4 DERMATOLOGY CLINICS & MEDICAL SPAS 390
12.3.1.1.5 TRAVEL RETAIL 390
12.3.1.1.6 OTHERS 390
12.3.1.2 NON STORE BASED 391
12.3.1.2.1 E-COMMERCE/PHARMACY WEBSITES 391
12.3.1.2.2 COMPANY-OWNED WEBSITES 391
12.4 OTHERS 391
13 GLOBAL NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY REGION 392
13.1 OVERVIEW 393
13.2 NORTH AMERICA 397
13.2.1 U.S. 419
13.2.2 CANADA 439
13.2.3 MEXICO 459
13.3 EUROPE 479
13.3.1 GERMANY 501
13.3.2 FRANCE 521
13.3.3 U.K. 541
13.3.4 ITALY 561
13.3.5 RUSSIA 581
13.3.6 SPAIN 601
13.3.7 BELGIUM 621
13.3.8 NETHERLANDS 641
13.3.9 DENMARK 661
13.3.10 SWITZERLAND 681
13.3.11 NORWAY 701
13.3.12 SWEDEN 721
13.3.13 FINLAND 741
13.3.14 TURKEY 761
13.3.15 POLAND 781
13.3.16 REST OF EUROPE 801
13.4 ASIA-PACIFIC 802
13.4.1 CHINA 824
13.4.2 JAPAN 842
13.4.3 SOUTH KOREA 861
13.4.4 INDIA 880
13.4.5 TAIWAN 898
13.4.6 AUSTRALIA 917
13.4.7 INDONESIA 937
13.4.8 SINGAPORE 956
13.4.9 NEW ZEALAND 975
13.4.10 THAILAND 994
13.4.11 MALAYSIA 1014
13.4.12 VIETNAM 1033
13.4.13 PHILIPPINES 1052
13.4.14 REST OF ASIA-PACIFIC 1071
13.5 SOUTH AMERICA 1072
13.5.1 BRAZIL 1093
13.5.2 ARGENTINA 1112
13.5.3 REST OF SOUTH AMERICA 1131
13.6 MIDDLE EAST & AFRICA 1132
13.6.1 U.A.E. 1157
13.6.2 SAUDI ARABIA 1179
13.6.3 QATAR NUCLEIC 1201
13.6.4 SOUTH AFRICA 1224
13.6.5 KUWAIT 1247
13.6.6 EGYPT 1269
13.6.7 BAHRAIN 1290
13.6.8 OMAN 1312
13.6.9 REST OF MIDDLE EAST AND AFRICA 133414 GLOBAL NUCLEIC ACID THERAPEUTICS MARKET, COMPANY LANDSCAPE 1335
14.1 COMPANY SHARE ANALYSIS: GLOBAL 1335
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 1336
14.3 COMPANY SHARE ANALYSIS: EUROPE 1337
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 1338
15 COMPANY PROFILES 1339
15.1 PFIZER INC. 1339
15.1.1 COMPANY SNAPSHOT 1339
15.1.2 REVENUE ANALYSIS 1339
15.1.3 COMPANY SHARE ANALYSIS 1340
15.1.4 PRODUCT PORTFOLIO 1340
15.1.5 RECENT DEVELOPMENTS 1340
15.2 BIOGEN 1341
15.2.1 COMPANY SNAPSHOT 1341
15.2.2 RECENT FINANCIALS 1341
15.2.3 COMPANY SHARE ANALYSIS 1342
15.2.4 PRODUCT PORTFOLIO 1342
15.2.5 RECENT DEVELOPMENTS/NEWS 1342
 
15.3 ALNYLAM PHARMACEUTICALS, INC. 1343
15.3.1 COMPANY SNAPSHOT 1343
15.3.2 RECENT FINANCIALS 1343
15.3.3 COMPANY SHARE ANALYSIS 1344
15.3.4 PRODUCT PORTFOLIO 1344
15.3.5 RECENT NEWS 1345
15.4 SAREPTA THERAPEUTICS, INC. 1346
15.4.1 COMPANY SNAPSHOT 1346
15.4.2 REVENUE ANALYSIS 1346
15.4.3 COMPANY SHARE ANALYSIS 1347
15.4.4 PRODUCT PORTFOLIO 1347
15.4.5 RECENT DEVELOPMENT 1347
15.5 IONIS PHARMACEUTICALS, INC. 1348
15.5.1 COMPANY SNAPSHOT 1348
15.5.2 REVENUE ANALYSIS 1348
15.5.3 COMPANY SHARE ANALYSIS 1349
15.5.4 PIPELINE PRODUCT PORTFOLIO 1349
15.5.5 RECENT DEVELOPMENTS 1350
15.6 ASTRAZENECA 1351
15.6.1 COMPANY SNAPSHOT 1351
15.6.2 RECENT FINANCIALS 1352
15.6.3 PIPELINE PRODUCT PORTFOLIO 1352
15.6.4 RECENT DEVELOPMENT 1354
15.7 MODERNA, INC. 1355
15.7.1 COMPANY SNAPSHOT 1355
15.7.2 RECENT FINANCIALS 1355
15.7.3 PIPELINE PRODUCT PORTFOLIO 1356
15.7.4 RECENT DEVELOPMENT 1356
15.8 NOVARTIS AG 1357
15.8.1 COMPANY SNAPSHOT 1357
15.8.2 REVENUE ANALYSIS 1358
15.8.3 PRODUCT PORTFOLIO 1358
15.8.4 RECENT DEVELOPMENTS 1359
15.9 SPARK THERAPEUTICS, INC. 1360
15.9.1 COMPANY SNAPSHOT 1360
15.9.2 PIPELINE PRODUCT PORTFOLIO 1360
15.9.3 RECENT DEVELOPMENT 1360
 
15.10 ZHEJIANG HAICHANG BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. 1361
15.10.1 COMPANY SNAPSHOT 1361
15.10.2 PIPELINE PRODUCT PORTFOLIO 1361
15.10.3 RECENT DEVELOPMENT 1362
16 GLOBAL NUCLEIC ACID SPORT FOOD ADDITIVES AND SKIN CARE MARKET: COMPANY LANDSCAPE 1363
16.1 COMPANY SHARE ANALYSIS: GLOBAL 1363
16.2 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 1364
16.3 COMPANY SHARE ANALYSIS: EUROPE 1365
16.4 COMPANY SHARE ANALYSIS: NORTH AMERICA 1366
17 COMPANY PROFILES 1367
17.1 REMY LAURE 1367
17.1.1 COMPANY SNAPSHOT 1367
17.1.2 COMPANY SHARE ANALYSIS 1367
17.1.3 PRODUCT PORTFOLIO 1368
17.1.4 RECENT DEVELOPMENT 1368
17.2 NEOVA 1369
17.2.1 COMPANY SNAPSHOT 1369
17.2.2 COMPANY SHARE ANALYSIS 1369
17.2.3 PRODUCT PORTFOLIO 1370
17.2.4 RECENT DEVELOPMENT 1373
17.3 MOONGLOW 1374
17.3.1 COMPANY SNAPSHOT 1374
17.3.2 COMPANY SHARE ANALYSIS 1374
17.3.3 PRODUCT PORTFOLIO 1375
17.3.4 RECENT DEVELOPMENT 1378
17.4 THE NAKED CHEMIST 1379
17.4.1 COMPANY SNAPSHOT 1379
17.4.2 COMPANY SHARE ANALYSIS 1379
17.4.3 PRODUCT PORTFOLIO 1380
17.4.4 RECENT DEVELOPMENT 1380
17.5 SKINSHIFT 1381
17.5.1 COMPANY SNAPSHOT 1381
17.5.2 COMPANY SHARE ANALYSIS 1381
17.5.3 PRODUCT PORTFOLIO 1382
17.5.4 RECENT DEVELOPMENT 1383
 
17.6 BIO JOUVANCE PARIS CONSUMER 1384
17.6.1 COMPANY SNAPSHOT 1384
17.6.2 PRODUCT PORTFOLIO 1384
17.6.3 RECENT DEVELOPMENT 1384
17.7 DNA SKIN INSTITUTE 1385
17.7.1 COMPANY SNAPSHOT 1385
17.7.2 PRODUCT PORTFOLIO 1385
17.7.3 RECENT DEVELOPMENT 1386
17.8 JULIETTE ARMAND 1387
17.8.1 COMPANY SNAPSHOT 1387
17.8.2 PRODUCT PORTFOLIO 1387
17.8.3 RECENT DEVELOPMENT 1387
17.9 KALICHEM S.R.L. 1388
17.9.1 COMPANY SNAPSHOT 1388
17.9.2 PRODUCT PORTFOLIO 1388
17.9.3 RECENT DEVELOPMENT 1388
17.10 NIPPON PAPER INDUSTRIES CO., LTD. 1389
17.10.1 COMPANY SNAPSHOT 1389
17.10.2 REVENUE ANALYSIS 1389
17.10.3 PRODUCT PORTFOLIO 1390
17.10.4 RECENT DEVELOPMENT 1390
17.11 POSTQUAM 1391
17.11.1 COMPANY SNAPSHOT 1391
17.11.2 PRODUCT PORTFOLIO 1391
17.11.3 RECENT DEVELOPMENT 1394
17.12 SHOPATDNA.COM 1395
17.12.1 COMPANY SNAPSHOT 1395
17.12.2 PRODUCT PORTFOLIO 1395
17.12.3 RECENT DEVELOPMENT 1396
18 QUESTIONNAIRE 1397
19 RELATED REPORTS 1400